Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BONCRESA vs ACTONEL WITH CALCIUM (COPACKAGED)
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
BONCRESA is a recombinant urate oxidase enzyme that catalyzes the oxidation of uric acid to allantoin, a more soluble and readily excreted metabolite, thereby reducing serum uric acid levels.
ACTONEL WITH CALCIUM (COPACKAGED) contains risedronate sodium, a bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite crystals in bone and inhibiting farnesyl pyrophosphate synthase (FPPS), an enzyme in the mevalonate pathway. This leads to reduced bone turnover and increased bone mineral density. The calcium component is for supplementation to prevent hypocalcemia.
Prophylaxis and treatment of hyperuricemia in adult patients receiving chemotherapy for hematologic malignancies at risk of tumor lysis syndrome (FDA-approved)
Treatment and prevention of postmenopausal osteoporosis,Treatment of glucocorticoid-induced osteoporosis,Treatment of Paget's disease of bone
5 mg orally once daily, with or without food; maximum dose 10 mg once daily.
Actonel (risedronate) 35 mg orally once weekly, taken with 6-8 oz of plain water at least 30 minutes before breakfast. Calcium supplement (e.g., 1250 mg calcium carbonate) taken with food at a different time of day.
Terminal elimination half-life: 12 hours (range 10-14 h); clinically relevant for once-daily dosing
Terminal elimination half-life of risedronate is approximately 20 hours for the 5 mg daily dose and 480 hours for the 35 mg weekly dose due to prolonged retention in bone; clinically, the drug accumulates in bone and is slowly released.
Rasburicase is a recombinant enzyme; not metabolized by hepatic enzymes. It is degraded by plasma proteases into small peptides and amino acids.
Risedronate is not metabolized and is eliminated unchanged primarily via renal excretion.
Renal: 70% unchanged; fecal: 20% as metabolites; biliary: minor (<5%)
Risedronate is eliminated primarily via renal excretion, with approximately 50% of an absorbed dose excreted unchanged in urine. Unabsorbed drug is eliminated in feces. Total clearance is about 100 m L/min.
95% bound to albumin and alpha-1-acid glycoprotein
Risedronate is approximately 24% bound to plasma proteins.
0.5 L/kg; indicates moderate tissue distribution
Volume of distribution for risedronate is approximately 6.3 L/kg, indicating extensive distribution into bone and other tissues.
Oral: 85% (high first-pass metabolism; absolute bioavailability 60% after oral administration)
Oral bioavailability of risedronate is low, averaging 0.63% for the 5 mg tablet when taken under fasting conditions; administration with food reduces bioavailability significantly (by up to 50%).
e GFR 30-59 m L/min: 2.5 mg once daily; e GFR 15-29 m L/min: 2.5 mg every other day; e GFR <15 m L/min or on dialysis: not recommended.
Contraindicated if Cr Cl <30 m L/min. For Cr Cl 30-49 m L/min: no dose adjustment needed. For Cr Cl ≥50 m L/min: no adjustment.
Child-Pugh A: no adjustment; Child-Pugh B: 2.5 mg once daily; Child-Pugh C: not recommended.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe impairment (Child-Pugh C).
Not approved for use in pediatric patients; safety and efficacy not established.
Not indicated for use in pediatric patients. Safety and efficacy not established.
No dose adjustment required solely based on age; monitor renal function and adjust according to GFR.
No specific dose adjustment required. Caution in patients with decreased renal function; monitor renal status. Increased risk of hypocalcemia if calcium intake inadequate.
WARNING: ANAPHYLAXIS AND HEMOLYSIS. Anaphylaxis has been reported with rasburicase (BONCRESA). Immediately discontinue if signs of anaphylaxis occur. Hemolysis has occurred in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency; contraindicated in patients with G6PD deficiency.
None
Risk of anaphylaxis, hemolysis (especially in G6PD deficiency), methemoglobinemia, interference with uric acid assays. Monitor for hypersensitivity reactions, have emergency equipment available. Do not administer as bolus injection; must be infused. Use caution in patients with known allergies or history of anaphylaxis.
Hypocalcemia must be corrected before therapy,Severe renal impairment (Cr Cl <30 m L/min) is not recommended,Esophageal irritation: instruct patients to swallow with full glass of water and not to lie down for 30 minutes,Osteonecrosis of the jaw (rare, mainly with cancer doses),Atypical femur fractures (rare, with long-term use),Avoid concomitant use with other bisphosphonates
Absolute: Known hypersensitivity to rasburicase or any excipients, G6PD deficiency (risk of hemolysis), history of hemolytic reactions to rasburicase, methemoglobinemia. Relative: None specifically mentioned.
Hypocalcemia,Severe renal impairment (Cr Cl <30 m L/min),Inability to sit or stand upright for at least 30 minutes,Hypersensitivity to risedronate or any component,Use in patients with esophageal abnormalities that delay emptying (e.g., stricture, achalasia)
Food, beverages other than plain water (e.g., coffee, juice, mineral water), and calcium supplements reduce absorption significantly. Take on an empty stomach, at least 30-60 minutes before any other oral intake. Avoid high-calcium foods (dairy, fortified products) around dosing time.
Risedronate absorption is significantly reduced by food, especially dairy products, calcium-rich foods, and beverages other than plain water. Avoid all food, beverages (except plain water), and other medications for at least 30 minutes after the dose. Calcium supplement should be taken with a meal to enhance absorption.
BONCRESA is contraindicated in pregnancy. In animal studies, it caused embryo-fetal mortality and malformations at doses below human exposure. First trimester: high risk of major congenital anomalies. Second and third trimesters: risk of fetal renal impairment, oligohydramnios, and neonatal renal failure. Avoid use during pregnancy.
Risedronate: Pregnancy Category C. Bisphosphonates accumulate in bone and are released slowly; theoretical risk of fetal skeletal abnormalities if exposure occurs before or during pregnancy. No adequate studies in pregnant women; use only if clearly needed. Calcium carbonate: Generally considered safe but excessive doses may cause hypercalcemia-related fetal risks. First trimester: Limited data, avoid if possible. Second/third trimester: Use only if maternal benefit outweighs fetal risk.
It is not known if BONCRESA is excreted in human milk. Due to potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during treatment and for at least 2 weeks after last dose. M/P ratio is unknown.
Risedronate: Unknown if excreted in human milk; not recommended due to potential for bone growth inhibition. Calcium: Excreted in breast milk at normal maternal intake levels; no adverse effects reported. M/P ratio: Unknown for risedronate; calcium M/P ratio approximately 1.1.
BONCRESA is contraindicated in pregnancy; no dose adjustment recommendations exist. Pharmacokinetic changes in pregnancy (e.g., increased volume of distribution, altered clearance) may theoretically reduce exposure, but use is not advised.
Risedronate: No specific dose adjustments are recommended in pregnancy due to lack of data; generally avoided. Calcium: No dose adjustment needed; maintain recommended daily intake (1000-1300 mg/day). Pregnancy may increase calcium absorption but no dose change required for supplementation.
BONCRESA (risedronate) is a bisphosphonate for osteoporosis. Administer on an empty stomach with plain water, at least 30 minutes before first food or drink. Ensure patient remains upright for 30-60 min to minimize esophageal irritation. Monitor renal function (Cr Cl <30 m L/min contraindicated). Consider calcium and vitamin D supplementation. Discontinue if severe bone, joint, or muscle pain occurs.
Actonel (risedronate) with calcium (copackaged) is used for osteoporosis. Administer risedronate on an empty stomach with plain water, at least 30 minutes before first food, drink, or other medications. Wait at least 30 minutes after risedronate before taking the calcium supplement. Calcium can interfere with risedronate absorption.
Take this medication on an empty stomach, first thing in the morning, with a full glass of plain water.,Do not eat, drink, or take other medications for at least 30 minutes after taking BONCRESA.,Stay upright (sitting or standing) for at least 30 minutes after taking to prevent esophageal irritation.,Swallow the tablet whole; do not crush, chew, or suck on it.,Report any difficulty or pain with swallowing, heartburn, or chest pain immediately.,Ensure adequate intake of calcium and vitamin D as directed by your healthcare provider.,Inform your doctor if you have kidney disease, trouble swallowing, or low blood calcium.,Notify your dentist of this medication before any dental procedures due to risk of osteonecrosis of the jaw.
Take the risedronate tablet first thing in the morning, at least 30 minutes before eating or drinking anything except plain water.,Swallow the risedronate tablet whole with a full glass of plain water (6-8 oz). Do not crush, chew, or suck the tablet.,Do not lie down for at least 30 minutes after taking risedronate to reduce risk of esophageal irritation.,After taking risedronate, wait at least 30 minutes before taking the calcium supplement provided in the copack.,Take the calcium supplement with food or after a meal to improve absorption and reduce stomach upset.,Report any symptoms of esophageal problems (difficulty or pain on swallowing, heartburn, or retrosternal pain) or jaw pain (possible osteonecrosis of the jaw).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BONCRESA vs ACTONEL WITH CALCIUM (COPACKAGED), answered by our medical review team.
BONCRESA is a Bisphosphonate that works by BONCRESA is a recombinant urate oxidase enzyme that catalyzes the oxidation of uric acid to allantoin, a more soluble and readily excreted metabolite, thereby reducing serum uric acid levels.. ACTONEL WITH CALCIUM (COPACKAGED) is a Bisphosphonate and Calcium Supplement that works by ACTONEL WITH CALCIUM (COPACKAGED) contains risedronate sodium, a bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite crystals in bone and inhibiting farnesyl pyrophosphate synthase (FPPS), an enzyme in the mevalonate pathway. This leads to reduced bone turnover and increased bone mineral density. The calcium component is for supplementation to prevent hypocalcemia.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BONCRESA and ACTONEL WITH CALCIUM (COPACKAGED) depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BONCRESA is: 5 mg orally once daily, with or without food; maximum dose 10 mg once daily.. The standard adult dose of ACTONEL WITH CALCIUM (COPACKAGED) is: Actonel (risedronate) 35 mg orally once weekly, taken with 6-8 oz of plain water at least 30 minutes before breakfast. Calcium supplement (e.g., 1250 mg calcium carbonate) taken with food at a different time of day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BONCRESA and ACTONEL WITH CALCIUM (COPACKAGED) in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BONCRESA is classified as Category C. BONCRESA is contraindicated in pregnancy. In animal studies, it caused embryo-fetal mortality and malformations at doses below human exposure. First trimester: high risk of major c. ACTONEL WITH CALCIUM (COPACKAGED) is classified as Category C. Risedronate: Pregnancy Category C. Bisphosphonates accumulate in bone and are released slowly; theoretical risk of fetal skeletal abnormalities if exposure occurs before or during . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.